Published in J Immunother on February 01, 2013
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell (2016) 2.84
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Current concepts in the diagnosis and management of cytokine release syndrome. Blood (2014) 2.63
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med (2015) 1.91
Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev (2014) 1.86
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med (2013) 1.76
Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med (2015) 1.58
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res (2014) 1.56
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50
Do no harm. Nat Biotechnol (2013) 1.45
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res (2014) 1.42
Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol (2013) 1.34
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
CAR T cells for solid tumors: armed and ready to go? Cancer J (2014) 1.29
Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res (2013) 1.15
Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A (2016) 1.08
Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget (2015) 1.07
Toxicities of chimeric antigen receptor T cells: recognition and management. Blood (2016) 1.07
HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A (2014) 1.06
A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther (2014) 1.05
Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med (2016) 1.03
Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology (2014) 1.03
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res (2015) 1.01
T-cell immunotherapy: looking forward. Mol Ther (2014) 1.00
The MAGE protein family and cancer. Curr Opin Cell Biol (2015) 1.00
Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol (2015) 0.98
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood (2015) 0.98
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2014) 0.96
Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol (2016) 0.96
The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol (2014) 0.95
Engineered T cells for cancer therapy. Cancer Immunol Immunother (2014) 0.95
Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev (2014) 0.94
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood (2013) 0.94
Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol (2014) 0.94
Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma. Oncotarget (2014) 0.94
New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell (2015) 0.93
Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy. J Natl Cancer Inst (2015) 0.92
Updates in Therapy for Advanced Melanoma. Cancers (Basel) (2016) 0.91
Adoptive T-cell therapy: adverse events and safety switches. Clin Transl Immunology (2014) 0.91
Is cancer gene therapy an empty suit? Lancet Oncol (2013) 0.90
Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res (2013) 0.89
Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res (2015) 0.89
Driving gene-engineered T cell immunotherapy of cancer. Cell Res (2016) 0.89
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer (2014) 0.89
Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel) (2013) 0.88
Engineering T cells for cancer: our synthetic future. Immunol Rev (2014) 0.88
T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells. Clin Exp Immunol (2015) 0.88
Genetically modified T cells for the treatment of malignant disease. Transfus Med Hemother (2013) 0.87
NKG2D CARs as cell therapy for cancer. Cancer J (2014) 0.87
Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. J Immunol (2015) 0.87
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther (2014) 0.87
Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.86
Strategies and developments of immunotherapies in osteosarcoma. Oncol Lett (2015) 0.86
Current advances in T-cell-based cancer immunotherapy. Immunotherapy (2014) 0.86
Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech (2015) 0.85
Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev (2016) 0.85
TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. J Clin Invest (2016) 0.85
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. Mol Ther (2016) 0.85
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84
Specific roles of each TCR hemichain in generating functional chain-centric TCR. J Immunol (2015) 0.84
Targeting neoantigens for cancer immunotherapy. Int Immunol (2016) 0.84
Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother (2015) 0.84
Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology (2015) 0.84
Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Pharmaceuticals (Basel) (2014) 0.84
In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies. Mol Ther Methods Clin Dev (2014) 0.84
Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype. Hum Gene Ther Methods (2014) 0.83
Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. J Immunother Cancer (2014) 0.83
RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol Ther (2014) 0.83
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
Clinical application of adoptive T cell therapy in solid tumors. Med Sci Monit (2014) 0.82
Antigen-specific T cell therapies for cancer. Hum Mol Genet (2015) 0.82
Specific increase in potency via structure-based design of a TCR. J Immunol (2014) 0.82
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Ann Oncol (2015) 0.82
Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Ther Adv Hematol (2015) 0.82
Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J (2015) 0.82
TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr Opin Immunol (2015) 0.82
Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer (2017) 0.81
Human Tumor Antigens and Cancer Immunotherapy. Biomed Res Int (2015) 0.81
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol (2016) 0.81
A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. Cancer Immunol Immunother (2014) 0.81
MAGE-A3-specific anticancer immunotherapy in the clinical practice. Oncoimmunology (2013) 0.81
Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy. Cancer Immunol Res (2015) 0.81
Immunotherapy of melanoma. EJC Suppl (2013) 0.81
Immunotherapy of Childhood Sarcomas. Front Oncol (2015) 0.81
Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol (2015) 0.81
Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. PLoS One (2014) 0.81
Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy (2014) 0.81
Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther (2015) 0.81
Are BiTEs the "missing link" in cancer therapy? Oncoimmunology (2015) 0.81
Reconstructing the immune system with lentiviral vectors. Virus Genes (2017) 0.81
T lymphocytes targeting native receptors. Immunol Rev (2014) 0.80
T cell engineering as therapy for cancer and HIV: our synthetic future. Philos Trans R Soc Lond B Biol Sci (2015) 0.80
Genetically modified T cells to target glioblastoma. Front Oncol (2013) 0.80
Progress and prospects for engineered T cell therapies. Br J Haematol (2014) 0.80
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol (2008) 15.90
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol (2006) 5.02
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther (2010) 4.54
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci (2009) 3.59
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol (2006) 3.15
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol (1999) 2.94
Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol (2009) 2.87
Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia. Biol Psychiatry (2006) 2.83
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 2.69
Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 2.66
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 2.63
Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain (2009) 2.00
Treating cancer with genetically engineered T cells. Trends Biotechnol (2011) 1.83
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A (2006) 1.82
Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol (2011) 1.72
Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med (2011) 1.72
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer (2001) 1.71
Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J Neurosci (2010) 1.69
Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr Protoc Mol Biol (2011) 1.68
Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol (2010) 1.65
GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine (2007) 1.58
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A (2012) 1.58
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Oligodendrocytes enforce immune tolerance of the uninfected brain by purging the peripheral repertoire of autoreactive CD8+ T cells. Immunity (2012) 1.50
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A (2008) 1.49
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol (2010) 1.45
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin Cancer Res (2010) 1.44
Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol (2011) 1.38
Melanoma-associated antigen genes - an update. Cancer Lett (2010) 1.36
Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate (2010) 1.21
Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med (2011) 1.19
Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res (2008) 1.18
MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res (2004) 1.17
High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer (2009) 1.16
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer (2011) 1.16
MAGE-A family: attractive targets for cancer immunotherapy. Vaccine (2011) 1.15
Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev (2002) 1.13
Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res (1992) 1.12
The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer (2006) 1.11
MAGE-A antigens as targets in tumour therapy. Cancer Lett (2012) 1.10
Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer (2007) 1.08
Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol (2011) 1.06
Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas (1992) 1.05
Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther (2008) 1.02
Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology (1998) 1.01
When MAGE meets RING: insights into biological functions of MAGE proteins. Protein Cell (2011) 1.00
Androgen receptor molecular biology and potential targets in prostate cancer. Ther Adv Urol (2010) 0.98
Evolution of the exon-intron structure and alternative splicing of the MAGE-A family of cancer/testis antigens. J Mol Evol (2004) 0.97
Neurologic complications of cancer and its treatment. Curr Oncol Rep (2010) 0.97
Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma. J Neurol Neurosurg Psychiatry (2003) 0.95
MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch Dermatol Res (2004) 0.95
Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology (1996) 0.88
MAGED1: molecular insights and clinical implications. Ann Med (2011) 0.88
Altered differentiation, diminished pathogenicity, and regulatory activity of myelin-specific T cells expressing an enhanced affinity TCR. J Immunol (2011) 0.82
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95